ATE216878T1 - Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet - Google Patents

Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet

Info

Publication number
ATE216878T1
ATE216878T1 AT96927588T AT96927588T ATE216878T1 AT E216878 T1 ATE216878 T1 AT E216878T1 AT 96927588 T AT96927588 T AT 96927588T AT 96927588 T AT96927588 T AT 96927588T AT E216878 T1 ATE216878 T1 AT E216878T1
Authority
AT
Austria
Prior art keywords
purinoceptors
agonists
antagonists
glutamate
cytotoxicity
Prior art date
Application number
AT96927588T
Other languages
English (en)
Inventor
Cinzia Volonte
Daniela Merlo
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Application granted granted Critical
Publication of ATE216878T1 publication Critical patent/ATE216878T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96927588T 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet ATE216878T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
PCT/EP1996/003254 WO1997004760A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity

Publications (1)

Publication Number Publication Date
ATE216878T1 true ATE216878T1 (de) 2002-05-15

Family

ID=11372076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927588T ATE216878T1 (de) 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet

Country Status (15)

Country Link
US (2) US6326370B1 (de)
EP (1) EP0841907B1 (de)
JP (1) JPH11511126A (de)
AT (1) ATE216878T1 (de)
AU (1) AU707808B2 (de)
BR (1) BR9609856A (de)
CA (1) CA2224293A1 (de)
DE (1) DE69621022T2 (de)
DK (1) DK0841907T3 (de)
ES (1) ES2173307T3 (de)
HK (1) HK1015698A1 (de)
IL (1) IL122915A (de)
IT (1) IT1277373B1 (de)
RU (1) RU2211707C2 (de)
WO (1) WO1997004760A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615202D0 (en) * 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
IT1303815B1 (it) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche Impiego di selettivi composti modulatori dei recettori purinici p2 perla prevenzione dei danni e della mortalita' causata da ischemia
US7141511B2 (en) * 2004-04-27 2006-11-28 Micron Technology Inc. Method and apparatus for fabricating a memory device with a dielectric etch stop layer
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
EP3323415A1 (de) * 2016-11-16 2018-05-23 Institut du Cerveau et de la Moelle Epiniere-ICM Behandlung neurodegenerativer erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4230493A1 (de) 1992-09-11 1994-03-17 Institut Fuer Bioanalytik Gmbh Arzneimittel zur Behandlung des zentralen Nervensystems

Also Published As

Publication number Publication date
ES2173307T3 (es) 2002-10-16
IL122915A (en) 2003-05-29
DE69621022T2 (de) 2003-02-27
DK0841907T3 (da) 2002-07-15
CA2224293A1 (en) 1997-02-13
HK1015698A1 (en) 1999-10-22
EP0841907A1 (de) 1998-05-20
AU707808B2 (en) 1999-07-22
ITMI951649A1 (it) 1997-01-27
IT1277373B1 (it) 1997-11-10
DE69621022D1 (de) 2002-06-06
RU2211707C2 (ru) 2003-09-10
BR9609856A (pt) 1999-03-16
ITMI951649A0 (it) 1995-07-27
WO1997004760A1 (en) 1997-02-13
IL122915A0 (en) 1998-08-16
JPH11511126A (ja) 1999-09-28
US20020028790A1 (en) 2002-03-07
US6326370B1 (en) 2001-12-04
EP0841907B1 (de) 2002-05-02
AU6736696A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
TW217407B (de)
AU3572797A (en) Screening compounds for the ability to alter the production of amyloid-beta peptide (x-$m(g)41)
EP0550631A4 (en) Compounds having antihypertensive and anti-ischemic properties
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
NO960973L (no) Mikropartikler inneholdende aktive materialer og gass
BR9812230A (pt) Artigo abrasivo, e, processos para produzir o mesmo, para reduzir uma superfìcie de uma peça de trabalho, e para utilizar um artigo abrasivo para reduzir a superfìcie de uma peça de trabalho
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
ATE216878T1 (de) Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet
GR3031241T3 (en) Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
GR3029370T3 (en) Compounds and methods for inhibition of hiv and related viruses
DE59707340D1 (de) Verhinderung und verzögerung der belagsbildung in membranprozessen
EP1032556A4 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
BR9809253A (pt) Processo para o ajuste de um leito fluidizado circulante e utilização do processo
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
HUP0102107A2 (hu) Szilárd üzemanyag-adalékok
WO1999052936A3 (en) Arginine peptide analogs useful as fibroblast growth factor antagonists
EP0380925A3 (de) Anzündsystem mit verbessertem Anzündverhalten
PT1103270E (pt) Tratamento de doencas auto-imunes em mamiferos
Parma et al. Effect of Storage Time on the Effectiveness of a Desulphurizing Mixture of Lime and Fluorite
RU99113527A (ru) Сплав для износостойкой наплавки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee